John-Philip Lawo

Altana AG, Wesel, North Rhine-Westphalia, Germany

Are you John-Philip Lawo?

Claim your profile

Publications (1)1.8 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: This 12-week, double-blind, parallel-group study compared the efficacy and safety of once daily ciclesonide and twice daily fluticasone propionate in patients aged 12-75 years with persistent asthma. Patients were randomized to once-daily ciclesonide 80 micro g (n = 278) or 160 micro g (n = 271), or twice daily fluticasone propionate 88 micro g (n = 259) (all ex-actuator). Significant improvements from baseline were seen in all three treatment groups for forced expiratory volume in 1 second, asthma symptom scores and rescue medication use (all p < 0.0001). Asthma exacerbation rates were low (each ciclesonide group, n = 2; fluticasone group, n = 1). Adverse event reporting indicated good tolerability. Once daily ciclesonide 80 micro g or 160 micro g showed comparable efficacy and tolerability to twice daily fluticasone propionate 88 micro g in persistent asthma.
    Journal of Asthma 09/2007; 44(7):555-63. DOI:10.1080/02770900701537081 · 1.80 Impact Factor

Publication Stats

21 Citations
1.80 Total Impact Points

Top Journals


  • 2007
    • Altana AG
      Wesel, North Rhine-Westphalia, Germany